NO954399L - 8-substituerte xanthiner som selektive adenosinreseptormidler - Google Patents

8-substituerte xanthiner som selektive adenosinreseptormidler

Info

Publication number
NO954399L
NO954399L NO954399A NO954399A NO954399L NO 954399 L NO954399 L NO 954399L NO 954399 A NO954399 A NO 954399A NO 954399 A NO954399 A NO 954399A NO 954399 L NO954399 L NO 954399L
Authority
NO
Norway
Prior art keywords
adenosine receptor
adenosine
iii
lower alkyl
receptor activity
Prior art date
Application number
NO954399A
Other languages
English (en)
Norwegian (no)
Other versions
NO954399D0 (no
Inventor
Norton Paul Peet
Nelson Lowell Lentz
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO954399D0 publication Critical patent/NO954399D0/no
Publication of NO954399L publication Critical patent/NO954399L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO954399A 1993-05-06 1995-11-03 8-substituerte xanthiner som selektive adenosinreseptormidler NO954399L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5852393A 1993-05-06 1993-05-06
PCT/US1994/004038 WO1994026744A1 (en) 1993-05-06 1994-04-13 8-substituted xanthines as selective adenosine receptor agents

Publications (2)

Publication Number Publication Date
NO954399D0 NO954399D0 (no) 1995-11-03
NO954399L true NO954399L (no) 1996-01-08

Family

ID=22017346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954399A NO954399L (no) 1993-05-06 1995-11-03 8-substituerte xanthiner som selektive adenosinreseptormidler

Country Status (14)

Country Link
US (1) US5734052A (fi)
EP (1) EP0697020A1 (fi)
JP (1) JPH08509977A (fi)
CN (1) CN1043473C (fi)
AU (1) AU676323B2 (fi)
CA (1) CA2159989C (fi)
FI (1) FI955257A (fi)
HU (1) HUT72327A (fi)
IL (1) IL109521A (fi)
MX (1) MX9403382A (fi)
NO (1) NO954399L (fi)
NZ (1) NZ265790A (fi)
WO (1) WO1994026744A1 (fi)
ZA (1) ZA943015B (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6258794B1 (en) 1999-12-14 2001-07-10 The Mclean Hospital Corporation Treatment of mental conditions including depression
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents

Also Published As

Publication number Publication date
US5734052A (en) 1998-03-31
AU676323B2 (en) 1997-03-06
EP0697020A1 (en) 1996-02-21
IL109521A (en) 1999-09-22
JPH08509977A (ja) 1996-10-22
CN1043473C (zh) 1999-05-26
NO954399D0 (no) 1995-11-03
AU6703294A (en) 1994-12-12
ZA943015B (en) 1995-01-30
CN1122599A (zh) 1996-05-15
FI955257A0 (fi) 1995-11-02
HUT72327A (en) 1996-04-29
MX9403382A (es) 1995-01-31
WO1994026744A1 (en) 1994-11-24
IL109521A0 (en) 1994-08-26
NZ265790A (en) 1996-10-28
CA2159989A1 (en) 1994-11-24
CA2159989C (en) 1994-11-24
FI955257A (fi) 1995-11-02
HU9503154D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
Vogelgesang et al. Stereoselective first‐pass metabolism of highly cleared drugs: studies of the bioavailability of L‐and D‐verapamil examined with a stable isotope technique.
US5117830A (en) Method of determining viability of tissue
HUP0301389A2 (hu) Purinszármazékok
US6995148B2 (en) Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US3879554A (en) Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders
NO954399L (no) 8-substituerte xanthiner som selektive adenosinreseptormidler
CA2038747A1 (en) Selective adenosine receptor agents
FI901549A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten fenyylialkyleeniaminosubstituoitujen puriini- ja pyratsolo/3,4-d/pyrimidiinijohdannaisten valmistamiseksi
CS156882A2 (en) Process for preparing derivatives of benzmide
ES8801280A1 (es) Procedimiento para la obtencion de benzo-(pirano y tiopirano)-piridinas
KR890014112A (ko) 퀴놀리진 및 퀴놀리지논 유도체의 심장 부정맥 치료용 의약품 제조에 있어서의 용도
NO823125L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2-amino-naftalen-derivater
BR9708171A (pt) Uso de derivados de 4-fenil-3,6-di-hidro-2h-piridila como bloqueadores de subtipo de receptor nmda
DK413188D0 (da) Benzimidazol-derivater til terapeutisk anvendelse og fremgangsmaade til fremstilling deraf
Scrutinio et al. Objective evaluation of gallopamil in patients with chronic stable angina. Exercise testing, Holter monitoring, cross-sectional echocardiography and plasma levels
EP0390111A3 (en) Selective adenosine receptor compounds
Desager et al. Relative acute cardiovascular toxicity induced by maprotiline, mianserin and nomifensine in conscious rabbits
NO951213L (no) 2-substituerte adenosiner med A-2-reseptoraffinitet
Cameron et al. Comparison of single doses of ketanserin and placebo in chronic stable angina.
RU92016587A (ru) Новые производные бензопирана, активатор калиевого канала

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application